 |
The Journal of the Japanese Society for Clinical Microbiology |
Biblioraphy Information
| ArticleTitle |
A case of acute cholangitis due to OXA-181 carbapenemase-producing Escherichia coli |
| Language |
J |
| AuthorList |
Yudai Taguchi1), Kyohei Sawai1), Nozomi Kanno1), Reiko Kudo1), Shunji Takahashi1), Taichi Murai2), Fumihiro Kodama3), Atsushi Nagasaka3), Yumiko Sakamoto4) |
| Affiliation |
1) Department of Laboratory, Sapporo City General Hospital
2) Department of Gastroenterology, Sapporo City General Hospital
3) Department of Infectious Diseases, Sapporo City General Hospital
4) Sapporo City Institute of Public Health |
| Publication |
J.J.C.M.: 32 (1), 50-56, 2022 |
| Received |
May 10, 2021 |
| Accepted |
September 2, 2021 |
| Abstract |
We report the case of acute cholangitis due to OXA-181 carbapenemase-producing Escherichia coli. Because of appropriate severity assessment based on the guideline and source control, the patient was cured with minimal exposure to antibiotics. E.coli and Klebsiella pneumoniae are the most common OXA-48 like carbapenemase producers and causal microorganisms of acute cholangitis. Therefore, it is predicted the more OXA-48 like carbapenemase encoding genes are diffused, the more acute cholangitis cases caused by OXA-48 like carbapenemase producers. OXA-48 like carbapenemase is known to hydrolyze penicillins and carbapenems, but not the extended spectrum cephalosporins. Hence, it is possible that extended spectrum cephalosporins are efficacy against OXA-48 like carbapenemase producers, in the absence of ESBL coproduction. However, we couldn't confirm ESBL production of the OXA-181 carbapenemase-producing strain from the phenotypes. In order to provide therapeutically useful reports based on carbapenemase activity, we suggest enhancing the genetic test that is performed in the laboratory. |
| Keywords |
Carbapenemase producing Enterobacterales |
|
